XGN:NASDAQExagen Inc. Analysis
Data as of 2026-09-18 - not real-time
$7.87
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Exagen Inc. trades at $7.87, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has gained 18.3% over the past 30 days. RSI sits at 65.7, which reads as approaching overbought, and MACD momentum is bearish. Recent trading has carved out support near $6.83 and resistance around $8.00.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 25.2% above where the shares trade now. Revenue is growing at 15.9% on a -26.6% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 54.3%, a beta of 2.25 and a maximum drawdown of 77.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 25.2% above where the shares trade now. Revenue is growing at 15.9% on a -26.6% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 54.3%, a beta of 2.25 and a maximum drawdown of 77.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
Top Market Events
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...Yahoo Finance1monExagen XGN Q2 2026 Earnings Call TranscriptOperator: Greetings, and welcome to the Exagen Inc.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 4.76
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 4.76
- Analyst targets imply +25.2% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Negative profit margin of -26.6%
- Analyst targets imply +25.2% versus the current price
- Negative return on equity of -113.8%
Key Metrics & Analysis
Financial Health
Revenue Growth15.90%
Profit Margin-26.61%
P/E Ratio-16.7
ROE-113.82%
ROA-14.92%
Debt/Equity226.39
P/B Ratio15.6
Op. Cash Flow$-6498000
Free Cash Flow$-1557000
Industry P/E30.2
Technical Analysis
TrendBullish
RSI65.7
Support$6.83
Resistance$8.00
MA 20$7.49
MA 50$6.23
MA 200$4.76
MACDBearish
VolumeDecreasing
Fear & Greed Index93.86
Valuation
Target Price$9.86
Upside/Downside25.25%
GradeFair
TypeGrowth
Risk Assessment
Beta2.25
Volatility54.34%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.